As reported on Healio, emerging real-world evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists—and related dual agonists—may play a significant role in lowering the risk of sleep apnea among individuals with obesity and type 2 diabetes. Findings from two large observational studies, published in Annals of the American Thoracic Society, indicate that these medications could offer protective benefits beyond their established roles in glycemic control and weight management.
Reduced Incidence of Sleep Apnea with GLP-1 Therapy
In one analysis leveraging the TriNetX global health database, investigators examined more than 1.2 million adults with obesity and/or type 2 diabetes. Patients who initiated GLP-1 receptor agonists or dual GLP-1/GIP therapies after June 2022 were compared with matched individuals who had not received these agents. Over an average follow-up of nearly three years, the use of these therapies was associated with a markedly lower likelihood of developing physician-diagnosed sleep apnea.
Overall, treatment with GLP-1–based agents was linked to roughly a 50% reduction in incident sleep apnea compared with nonuse. This trend held across individual medications within the class, including semaglutide, dulaglutide, tirzepatide, and liraglutide, although the magnitude of effect varied. Dulaglutide and semaglutide demonstrated stronger associations, whereas liraglutide showed less consistent statistical significance in certain subgroups.
Importantly, the benefit was observed across a wide range of patient populations, including both men and women, as well as individuals with varying degrees of obesity. Interestingly, the protective effect appeared more pronounced in those with lower BMI thresholds compared with those with more severe obesity, suggesting that earlier intervention may yield greater preventive value.
An exploratory component of this study also found a significantly reduced need for positive airway pressure therapy among individuals treated with GLP-1 or dual agonists, further supporting a potential role in mitigating disease severity or progression.
Semaglutide Shows Specific Promise in OSA Prevention and Outcomes
A second study focused specifically on semaglutide and its relationship to obstructive sleep apnea (OSA). Using a similarly robust dataset, researchers evaluated two patient cohorts: individuals with obesity but no prior OSA diagnosis, and those already diagnosed with both obesity and OSA.
Among patients with obesity alone, semaglutide use was associated with a meaningful reduction in the risk of newly diagnosed OSA over approximately one year of follow-up. This association remained consistent across multiple subgroups, including age categories, BMI ranges, and comorbid conditions such as diabetes, heart failure, and chronic kidney disease.
Beyond prevention, semaglutide was also linked to improved clinical outcomes. In patients with obesity, the drug was associated with lower risks of all-cause mortality, major cardiovascular events, and significant kidney complications. Similar benefits were observed in those with established OSA, where semaglutide use corresponded to reductions in the same composite outcomes.
Mechanisms and Clinical Implications
While the precise mechanisms underlying these findings remain under investigation, weight loss is likely a central contributor. GLP-1 receptor agonists are known to induce substantial and sustained reductions in body weight, which can alleviate upper airway obstruction—a key driver of OSA. However, researchers suggest that additional metabolic and anti-inflammatory effects may also contribute.
“These results highlight the potential for GLP-1–based therapies to extend beyond traditional indications,” the investigators noted, emphasizing their relevance for prevention strategies in high-risk populations. At the same time, they cautioned that the observational design of these studies limits causal interpretation.
Next Steps
Experts agree that randomized controlled trials will be essential to confirm these findings and clarify the mechanisms at play. Future studies incorporating sleep studies, biomarker analysis, and long-term outcomes will help determine whether GLP-1 therapies should be formally integrated into sleep apnea prevention or management strategies.
For clinicians, the accumulating evidence reinforces the broader systemic benefits of GLP-1 receptor agonists in patients with obesity. As their use continues to expand, their potential role in reducing sleep-related breathing disorders may become an increasingly important consideration in comprehensive metabolic care.
